Skip to content
Triangle logo TriangleGet started
← Study library

NCT03010358 · REGISTRY CONDITION SEARCH

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2023-08-08

This phase I/II trial studies the side effect and best dose of entospletinib when giving together with obinutuzumab and to see how well they work in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma that has come back. Entospletinib may stop the growth of cancer cells by blocking some of the enzymes need for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Giving entospletinib and obinutuzumab together may work better in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Maximum Tolerated Dose (MTD) of Entospletinib in Combination With Obinutuzumab

→

outcome · POSTED

Complete Response (CR) Defined as the Percentage of Subjects Who Achieve CR

→

outcome · POSTED

Objective Response Rate (ORR)

→

outcome · POSTED

Event Free Survival (EFS)

→

outcome · POSTED

Number of Participants Who Experienced Adverse Events

→

outcome · POSTED

Peripheral Blood B-cell Depletion and Recovery

→

outcome · NOT POSTED

Pharmacodynamics Parameters of NFkappaB Activation and Expression of Anti-apoptotic Proteins in Chronic Lymphocytic Leukemia (CLL) Cells

→

outcome · NOT POSTED

Biomarkers (Chromosomal Abnormalities, IGHV Mutational Status, p53 Mutational Status)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Phase I portion of the study: Histologically or flow cytometry confirmed diagnosis of B-CLL/SLL according to National Cancer Institute (NCI)-Working Group (WG) 1996 guidelines * Phase I portion of the study: The following types of NHL as documented by medical records and with histology based on criteria established by the World Health Organization (WHO): * Mantle cell lymphoma (MCL) * Follicular lymphoma (FL) - grades 1-3a * Lymphoplasmacytic lymphoma (LPL) * Marginal zone lymphoma (MZL) * CLL in Richter's transformation * B-cell prolymphocytic leukemia * Phase I portion of the study: Patients with histologically confirmed classical hairy cell leukemia (HCL) * Phase II portion of the study - histologically or flow cytometry confirmed diagnosis of BCLL/SLL according to NCI-WG 1996 guidelines; patients who lack CD23 expression on their leukemia cells should be examined for (and found NOT to have) either t(11;14) or cyclin D1 overexpression, to rule out mantle cell lymphoma * Patients underwent \>= 1 prior chemotherapy-based or immunotherapy-based regimen or targeted therapy (e.g., inhibitors of BTK, PI3K etc.) administered for \>= 2 cycles, and have had either documented disease progression or no response (stable disease) to the most recent treatment regimen * Patients with CLL/SLL must demonstrate active disease meeting at least 1 of the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for requiring treatment: * A minimum of any one of the following constitutional symptoms: * Unintentional weight loss \> 10% within the previous 6 months prior to screening * Extreme fatigue (unable to work or perform usual activities) * Fevers of greater than 100.5 Fahrenheit (F) for \>= 2 weeks without evidence of infection * Night sweats without evidence of infection * Evidence of progressive marrow failure as manifested by the development of, or worsening of anemia or thrombocytopenia * Massive (i.e., \> 6 cm below the left costal margin), progressive or symptomatic splenomegaly * Massive nodes or clusters (i.e., \> 10 cm in longest diameter) or progressive lymphadenopathy * Progressive lymphocytosis with an increase of \> 50% over a 2-month period, or an anticipated doubling time of less than 6 months * Autoimmune anemia or thrombocytopenia that is poorly responsive to corticosteroids * Patients with HCL must be intolerant of or not candidates for purine analog-based therapy, or failed to achieve response (CR or partial response \[PR\]) or relapsed within 2 years of such therapy, AND meet the standard treatment initiation criteria (absolute neutrophil count \[ANC\] =\< 1000/uL, hemoglobin \[Hgb\] =\< 10 g/dL, platelet count =\< 100,000/uL); patients with indolent lymphoma (FL, LPL, MZL) and patients with B-cell prolymphocytic leukemia must have an indication for treatment in the opinion of the investigator; patients with MCL and patients with CLL in Richter's transformation should have previously received or not be candidates for high dose chemotherapy/autologous stem cell transplant * For diseases other than CLL, LPL, and HCL, presence of radiographically measurable lymphadenopathy or extra-nodal lymphoid malignancy (defined as the presence of \>= 1 lesion that measures \>= 2.0 cm in the longest dimension \[LD\] and \>= 1.0 cm in the longest perpendicular dimension \[LPD\] as assessed by computed tomography \[CT\] or magnetic resonance imaging \[MRI\]); for LPL, measurable disease will be defined as serum monoclonal IgM \> 0.5 g/dL or meeting at least 1 of the recommendations from the Second International Workshop on LPL for requiring treatment * Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Direct bilirubin =\< 2 X institutional upper limit of normal (ULN) (unless due to known Gilbert's syndrome or compensated hemolysis directly attributable to CLL) * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) less than 2.5 X institutional ULN * Estimated creatinine clearance (CrCL) using the Cockcroft-Gault equation \>= 50 mL/min * Platelets \>= 50,000/mm\^3 independent of transfusion support, with no active bleeding * Absolute neutrophil count (ANC) \>= 1000/mm\^3, unless due to disease involvement in the bone marrow * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Prior therapeutic intervention with any of the following: * Therapeutic anticancer antibodies within 4 weeks (rituximab), except within 6 months for obinutuzumab or a similar investigational type II monoclonal antibody; * Radio- or toxin-immunoconjugates within 10 weeks; * Inhibitors of BTK (ibrutinib), PI-3K (idelalisib), BH3-mimetic venetoclax, lenalidomide and other "targeted" therapy (including but not limited to investigational BTK and PI-3K inhibitors, etc.) - within 6 half-lives (i.e., 36 hours for ibrutinib) * All other chemotherapy, radiation therapy within 3 weeks prior to initiation of therapy * SYK inhibitors at any time * Inadequate recovery from adverse events related to prior therapy to grade =\< 1 (excluding grade 2 alopecia and neuropathy) * Chronic use of corticosteroids in excess of prednisone 30 mg/day or its equivalent * Stem cell transplant recipients must have no evidence of and not receive treatment for graft-versus-host disease * Concomitant use or use in the prior two weeks of moderate or strong CYP3A and CYP2C9 inducers or strong CYP2C9 inhibitors, including nutraceutical preparations, e.g., grapefruit juice and St John's wort * History prior malignancy except: * Malignancy treated with curative intent and no known active disease present for \>= 2 years prior to initiation of therapy on current study * Adequately treated non-melanoma skin cancer or lentigo maligna (melanoma in situ) without evidence of disease * Adequately treated in situ carcinomas (e.g., cervical, esophageal, etc.) without evidence of disease * Asymptomatic prostate cancer managed with "watch and wait" strategy * Myelodysplastic syndrome which is clinically well controlled and no evidence of the cytogenetic abnormalities characteristic of myelodysplasia on the bone marrow at screening * Uncontrolled immune hemolysis or thrombocytopenia (positive direct antiglobulin test in absence of hemolysis or history of immune-mediated cytopenias are not exclusions) * History of human immunodeficiency virus (HIV) infection or active hepatitis B or C * Major surgery (requiring general anesthesia) within 2 weeks prior to initiation of therapy * Inability to swallow and retain an oral medication; patients with clinically significant medical condition of malabsorption, inflammatory bowel disease, chronic conditions which manifest with diarrhea, refractory nausea, vomiting or any other condition that will interfere significantly with drug absorption are excluded; patients must also have adequate venous access * Need for ongoing therapy with proton pump inhibitors; H2 antagonists are allowed * Active uncontrolled infection * Women who are pregnant or lactating * Fertile men or women of childbearing potential unless 1) permanently sterile or 2) using a highly effective measure of contraception such as condoms in males and consistent and correct use of one of the following in females: intrauterine device, tubal sterilization, Essure micro-insert system, vasectomy in the male partner; effective contraception is required for males during treatment with study drug and to continue for 3 months after the last dose of either entospletinib or obinutuzumab, whichever is later; for women, effective contraception is required to continue for 18 months after the last dose of obinutuzumab or for 30 days after the last dose of entospletinib, whichever is later * Definition of childbearing potential: for this study, a female subject is considered of childbearing potential until becoming post-menopausal unless permanently sterile or with medically documented ovarian failure; women are considered to be in a postmenopausal state when \>= 54 years of age with cessation of previously occurring menses for \>= 12 months without an alternative cause; women of any age with amenorrhea of \>= 12 months may also be considered post-menopausal if their follicle stimulating hormone (FSH) level is in the post-menopausal range and they are not using hormonal contraception or hormonal replacement therapy; permanent sterilization in females includes hysterectomy, bilateral oophorectomy, or bilateral salpingectomy in a female subject of any age; permanent sterilization in males include bilateral orchiectomy or medical documentation of alternative explanation * Any condition for which participation in the study is judged by the Investigator to be detrimental to the patient with inter-current illness or psychiatric/social situations that would jeopardize compliance with study requirements
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive entospletinib PO either QD or BID on days -7 to -1 (run-in phase) depending on the assigned dose level. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of the first cycle, and on day 1 of subsequent cycles. Treatment with obinutuzumab repeats every 28 days for up to 6 cycles and daily treatment with entospletinib continues every 28 days for up to 12 cycles in the absence of disease progression or unexpected toxicity.
    intervention Names
    1. Drug: Entospletinib
    2. Other: Laboratory Biomarker Analysis
    3. Biological: Obinutuzumab
    4. Other: Pharmacological Study
    label
    Treatment (entospletinib, obinutuzumab)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (entospletinib, obinutuzumab)
    description
    Given PO
    name
    Entospletinib
    other Names
    1. ENTO
    2. GS 9973
    3. GS-9973
    type
    DRUG
  2. arm Group Labels
    1. Treatment (entospletinib, obinutuzumab)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  3. arm Group Labels
    1. Treatment (entospletinib, obinutuzumab)
    description
    Given IV
    name
    Obinutuzumab
    other Names
    1. Anti-CD20 Monoclonal Antibody R7159
    2. GA-101
    3. GA101
    4. Gazyva
    5. huMAB(CD20)
    6. R7159
    7. RO 5072759
    8. RO-5072759
    9. RO5072759
    type
    BIOLOGICAL
  4. arm Group Labels
    1. Treatment (entospletinib, obinutuzumab)
    description
    Correlative studies
    name
    Pharmacological Study
    type
    OTHER
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
24
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    Will be summarized using descriptive statistics.
    measure
    Peripheral Blood B-cell Depletion and Recovery
    time Frame
    Up to 45 months
  2. description
    Pharmacokinetic parameters including peak and trough levels will be determined by noncompartmental method(s) using the pharmacokinetic profile of entospletinib and obinutuzumab.
    measure
    Pharmacodynamics Parameters of NFkappaB Activation and Expression of Anti-apoptotic Proteins in Chronic Lymphocytic Leukemia (CLL) Cells
    time Frame
    Up to 45 months
  3. description
    Will be assessed by IgH somatic hypermutation assay version 2.0. Will associate with response (ORR) to entospletinib (ENTO) in combination with obinutuzumab in patients with relapsed/refractory CLL.
    measure
    Biomarkers (Chromosomal Abnormalities, IGHV Mutational Status, p53 Mutational Status)
    time Frame
    Up to 45 months
primary Outcomes
  1. description
    The dose of obinutuzumab remains fixed in standard doses while the dose of entospletinib will be escalated. The starting dose of entospletinib will be 200 mg (twice-daily) and escalated to the second dose level 400 mg (twice-daily). MTD is the dose associated with a total of 6 patients treated with less than 2 dose limiting toxicities (DLT), or a total of 3 patients treated with less than 1 DLT. DLT is defined as 1) grade 3 or higher non-hematological toxicity (except grade 3 nausea, vomiting or diarrhea that was reversible within 72 hours with supportive care; grade 3 infusion-related toxicity; asymptomatic grade 3-4 laboratory abnormalities that are reversible to grade 2 or less within 72 hours; grade 3 tumor lysis syndrome or hyponatremia); 2) grade 4 neutropenia lasting \>7 days or febrile neutropenia; or 3) grade 4 thrombocytopenia/anemia or grade 3 thrombocytopenia with bleeding. The dosage follows the 3+3 traditional escalation rules.
    measure
    Maximum Tolerated Dose (MTD) of Entospletinib in Combination With Obinutuzumab
    time Frame
    Up to 28 days
  2. description
    Response for CLL/SLL measured using Modified International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 (IWCLL) guidelines. Response for hairy cell leukemia was measured using Consensus resolution: proposed criteria published in Leukemia 1987.
    measure
    Complete Response (CR) Defined as the Percentage of Subjects Who Achieve CR
    time Frame
    Up to 45 months
secondary Outcomes
  1. description
    Defined as percentage of participants with complete remission, complete response with incomplete marrow recovery, partial remission and nodular partial response. Response for CLL/SLL measured using Modified International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 (IWCLL) guidelines. Response for hairy cell leukemia was measured using Consensus resolution: proposed criteria published in Leukemia 1987.
    measure
    Objective Response Rate (ORR)
    time Frame
    Up to 45 months
  2. description
    Will be summarized descriptively using the Kaplan-Meier estimate. EFS will be censored if entospletinib is discontinued for other reasons (such as drug is no longer available).
    measure
    Event Free Survival (EFS)
    time Frame
    The interval between the date of first study treatment and the date of objective signs of disease recurrence, subsequent anti leukemic therapy, or death, whichever is first reported, assessed up to 45 months.
  3. description
    Will be assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Will be summarized for the safety population separately for phase 1 and phase 2 portions by dose level. All adverse events (AEs) will be coded by system organ class, Medical Dictionary for Regulatory Activities (MedDRA) preferred term, and severity grade using NCI CTCAE (version 4.03).
    measure
    Number of Participants Who Experienced Adverse Events
    time Frame
    Up to 45 months
Full study description
brief Summary
This phase I/II trial studies the side effect and best dose of entospletinib when giving together with obinutuzumab and to see how well they work in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma that has come back. Entospletinib may stop the growth of cancer cells by blocking some of the enzymes need for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Giving entospletinib and obinutuzumab together may work better in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma.
detailed Description
PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of entospletinib administered in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and non-Hodgkin lymphoma (NHL), and identify the dose for phase 2 expansion. (Phase I) II. To evaluate the efficacy of entospletinib in combination with obinutuzumab in patients with relapsed or refractory CLL/SLL, as measured by complete response (CR) rate. (Phase II) SECONDARY OBJECTIVES: I. Objective response rate (ORR, defined as complete remission, complete response with incomplete marrow recovery, partial remission and nodular partial response). (Phase II) II. Event free survival defined as the interval between the date of first study treatment and the date of objective signs of disease recurrence, subsequent anti-leukemic therapy, or death, whichever is first reported. (Phase II) III. Safety and tolerability of entospletinib in combination with obinutuzumab by adverse events (AEs). (Phase II) EXPLORATORY OBJECTIVES: I. Peripheral blood B-cell depletion and recovery. II. Pharmacodynamics effects of in vivo administration of entospletinib on NFkappaB activation and expression of anti-apoptotic proteins in CLL cells. III. Association of established biomarkers (chromosomal abnormalities, immunoglobulin heavy chain \[IGHV\] mutational status, p53 mutational status) with response (ORR and event-free survival \[EFS\]) to entospletinib (ENTO) in combination with obinutuzumab in patients with relapsed/refractory CLL. OUTLINE: This is a phase I, dose-escalation study of entospletinib followed by a phase II study. Patients receive entospletinib orally (PO) either once a day (QD) or twice a day (BID) on days -7 to -1 (run-in phase) depending on the assigned dose level. Patients also receive obinutuzumab intravenously (IV) on days 1, 2, 8, and 15 of the first cycle and on day 1 of all subsequent cycles. Treatment with obinutuzumab repeats every 28 days for up to 6 cycles and daily treatment with entospletinib continues every 28 days for up to 12 cycles in the absence of disease progression or unexpected toxicity. After completion of study treatment, patients are followed up every 3 months for 12 months then every 6 months thereafter. In the event of study closure, patients who are receiving study drug at the time of closure will complete an abbreviated End of Treatment (EOT) visit. No additional follow up will occur.
Source references
references
  1. citation
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56. doi: 10.1182/blood-2007-06-093906. Epub 2008 Jan 23.
    pmid
    18216293
    type
    BACKGROUND
  2. citation
    Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia. Leukemia. 1987 Apr;1(4):405. No abstract available.
    pmid
    3669765
    type
    BACKGROUND
  3. citation
    Lam V, Best S, Kittai A, Orand K, Spurgeon SE, Liu T, Danilov AV. Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol. 2022 Feb;88(2):836-841. doi: 10.1111/bcp.14962. Epub 2021 Jul 19.
    pmid
    34196037
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-7b77c63845c5818938d5
      requested nct id
      NCT03010358
      primary nct id
      NCT03010358
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
      payload sha256
      94834cd7ce7c4262e49d62562212fecc04be6f4f6178d1133bdda69274ed1ae7
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-7b77c63845c5818938d5
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03010358
      occurrences
      1. context exact
        NCT03010358
        end
        11
        exact text
        NCT03010358
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hairy Cell Leukemia
      query disease state id
      ds-hairy-cell-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hairy-cell-leukemia-000.json
      source file sha256
      8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
      source json pointer
      /studies/44/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      f8a3cc9d4fb412b2e174fba895728dcd4311331f8f6e2514ebcfbc5145b96146

    Preserved source evidence · Not medical advice